Latest Influenza treatment Stories
Biota Holdings has announced that its second generation, influenza treatment, CS-8958, has successfully completed its initial Phase II clinical evaluation, showing favorable outcomes against all measured endpoints.
Biota Holdings Limited (ASX: BTA) today announced that its second generation, influenza treatment, CS-8958, has successfully completed its initial Phase II clinical evaluation, showing favourable outcomes against all measured endpoints.
GlaxoSmithKline Plc's prescription flu treatment Relenza has won U.S. approval for preventing influenza in adults and children ages 5 and older, regulators said on Wednesday.
U.S. health officials on Wednesday said they have purchased more than 14 million courses of antiviral treatments from Roche Holding AG and GlaxoSmithKline Plc in preparation for a possible avian flu pandemic among humans.
CHICAGO (Reuters) - Misuse of two anti-viral drugs in China, Russia and other countries likely led to the development of resistant influenza strains against which the drugs are now nearly useless, health experts said on Thursday.
Swiss drugmaker Roche Holding AG has received approval in the European Union for its Tamiflu treatment to be used to prevent influenza in children aged from one to 12 years, the firm said on Tuesday.
Swiss drug maker Roche Holding AG said on Tuesday it had lifted restrictions on shipments of influenza drug Tamiflu that were put in place to prevent hoarding by consumers worried about bird flu.
Tamiflu, the drug which many governments have stockpiled to ward off a deadly bird flu pandemic, appears to be an effective treatment for the disease if administered early enough, its maker Roche Holding AG said.
By Tom Armitage ZURICH (Reuters) - Roche, main producer of the drug thought to be the best defense against a possible pandemic caused by bird flu, has settled a dispute with the drug's inventor over production and royalties, the companies said on Wednesday.
NEW YORK (Reuters Health) - During outbreaks of influenza A, treating children with the antiviral drug amantadine is likely to be a cost-effective measure if treatment begins within 48 hours of symptom onset, especially if it allows quicker return to school and parents' return to work, investigators report.
The common cold is a viral disease of the upper respiratory system, caused primarily by rhinoviruses and coronaviruses. Symptoms usually include a cough, sore throat, runny nose, and a fever. There is no known treatment to shorten the duration of the virus yet the cold normally dissipates after 7 to 10 days. It is the most common infectious disease in humans who on average are infected two to four times a year in adults. It can also be called a upper respiratory tract infection. Other...